Twelve or 30 Months of Dual Antiplatelet Therapy after Drug-Eluting Stents
New England Journal of Medicine2014Vol. 371(23), pp. 2155–2166
Citations Over TimeTop 1% of 2014 papers
Laura Mauri, Larry S. Dean, Robert W. Yeh, Priscilla Driscoll-Shempp, Donald E. Cutlip, Philippe Gabríel Steg, Sharon‐Lise T. Normand, Eugene Braunwald, Stephen D. Wiviott, David J. Cohen, David R. Holmes, Mitchell W. Krucoff, James Hermiller, Harold L. Dauerman, Daniel I. Simon, David E. Kandzari, Kirk N. Garratt, David P. Lee, Thomas Pow, Peter Ver Lee, Michael J. Rinaldi, Joseph M. Massaro
Abstract
Dual antiplatelet therapy beyond 1 year after placement of a drug-eluting stent, as compared with aspirin therapy alone, significantly reduced the risks of stent thrombosis and major adverse cardiovascular and cerebrovascular events but was associated with an increased risk of bleeding. (Funded by a consortium of eight device and drug manufacturers and others; DAPT ClinicalTrials.gov number, NCT00977938.).
Related Papers
- → High on-thienopyridine platelet reactivity in elderly coronary patients: the SENIOR-PLATELET study(2011)138 cited
- → Switching from Clopidogrel to Prasugrel in patients undergoing PCI: A meta-analytic overview(2015)6 cited
- → Novel oral antiplatelets for acute coronary syndrome(2013)
- → Acute coronary syndrome: potent oral antiplatelets(2013)
- Application of prasugrel in coronary interventional therapy(2012)